NOI-RML-E-1854322

NAICS - 325414

66 -

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with BioXCel, West Lebanon, NH to produce custom production of monoclonal antibodies against Dengue virus.

These custom antibodies will be used in support current Dengue virus vaccine research that is taking place in the EMERGING RESPIRATORY VIRUSES SECTION of LID. Place of delivery is Bethesda, MD 20892.

# DESCRIPTION/PRODUCTION OF:
1 DEN1 1F1 100 mg
2 DEN2 3H5 100 mg
3 DEN3 8A1 100 mg
4 DEN4 1H10-NIH 100 mg
5 DEN 2H2 100 mg
6 Pilot study

The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-RML-E-1854322) to Jesse Weidow at [email protected], by 5:00 pm eastern standard time Monday, June 12, 2017. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.